Current and Future Oncology Management in the United States

2020-02-26T13:56:46+00:00February 1st, 2019|Categories: Blog|Tags: , |

The cost of treating cancer patients is high and rising in the United States. Payers are exposed to cost through doctor visits, laboratory tests, imaging tests, radiation treatment, drugs, hospital stays, surgery, home care, transportation and travel, and caregiving. This study focuses on the cost of medication from the viewpoint of U.S. payers. Although new tools for managing these costs have been gaining attention, prices continue to rise, and [...]

Comparison of US and EU approaches to Oncology Management

2020-02-26T14:24:30+00:00September 10th, 2018|Categories: Blog|Tags: , |

It was great meeting all of you who were able to stop by our booth in Glasgow! It was a great experience to present our findings to the industry innovators at ISPOR. The themes of early data evaluation and subsequent real word evaluations for management decision-making emerged throughout the day. We look forward to continuing our work in understanding trends and the feasibility of management strategies globally. [...]

Key Learnings on Pathways of Care

2020-02-26T14:55:49+00:00August 1st, 2018|Categories: Blog|Tags: , , |

Oncology is a high cost and high management priority disease state for US payers, however, ability to control cost in this space is limited. MKO Global Partners, a Two Labs Company, conducted previous research that suggests oncology drugs are primarily managed to label and only occasionally are there policies in place to restrict or prefer certain agents. However, new ways to control the cost of oncology care are emerging [...]

Management and Budget Impact

2020-02-28T14:55:43+00:00March 13th, 2017|Categories: Blog|Tags: , , |

With the evolution of payer management in different specialty classes, MKO has been tracking management priority and budget impact using our M Tracker. M Tracker has revealed a significant change in oncology and HCV management in the first half of 2017. Here is a preview of current payer opinions on specialty disease management, using our proprietary M Tracker data. Click HERE to see the animation [...]

NHS England Overhauls Access to Cancer Treatments

2020-02-28T15:00:51+00:00June 30th, 2016|Categories: Blog|Tags: , , , |

Patients in England could have faster access to effective cancer treatments through the reincarnated Cancer Drugs Fund (CDF), the National Institute for Health and Care Excellence (NICE) has announced. The new fund will replace the existing – and greatly overspent – service, which provides access to cancer drugs that are not routinely available at the National Health Service (NHS) in England. Its costs rose to £340 million between 2015 [...]

T-Cell Immunotherapy Market Predicted To Grow

2020-02-28T15:01:35+00:00April 21st, 2016|Categories: Blog|Tags: , , |

Nearly one million people are diagnosed with cancer in the United States per year, according to The American Cancer Society, and although cancer therapeutics are among the most active areas in drug development, treatment still falls short of meeting patients’ needs. However, experts believe that immunotherapeutics – in particular T-cell immunotherapy – could help fill a vital gap, with Roots Analysis’ "T-Cell Immunotherapy Market, 2015-2030" report predicting the market [...]

British Pharma Industry Faces Challenges Post-Brexit

2020-02-28T15:02:28+00:00February 12th, 2016|Categories: Blog|Tags: , , , |

The British pharmaceutical industry is facing new challenges following the UK’s decision to leave the European Union, a white paper has revealed. Published by Global Data, it warned of wide-reaching impacts. 51% of Britain’s medicinal and pharmaceutical products are exported to the European Union (EU). But in June, a referendum indicated the UK should leave the EU – the so-called “Brexit”. While Big Pharma companies emerged from the vote largely [...]

New Cancer Drugs Fuel Debate over Drug Testing Process

2020-02-28T15:05:26+00:00October 17th, 2013|Categories: Blog|Tags: , , , |

Question: If the results of initial testing on a drug are amazing – and could mean the difference between life and death – should pharmaceutical companies be required to go through the current long and costly process of drug testing before making it available to the public?  If a drug is fine-tuned to treat a specific genetic profile, does it make sense to do randomized controlled trials, even if [...]

Do We Need Phase III Randomized Controlled Trials for EVERYTHING?

2020-02-28T15:57:21+00:00September 23rd, 2013|Categories: Blog|Tags: , , |

Targeted therapy agents In clinical trials of targeted therapy agents, sometimes the target is such a crucial driver of the neoplastic process, that its inhibition is able to stop the growing tumor in its tracks. This appears to be the case for some recently approved agents such as vemurafenib for BRAF V600E melanoma and crizotinib for ALK+ NSCLC. Careful screening of patients for these mutations ensures the likelihood of improved [...]

Defining Success in Clinical Trials: Is Learning Something Enough?

2020-02-28T16:02:09+00:00July 25th, 2013|Categories: Blog|Tags: , , |

At last month’s ASCO conference, rapt attention was given to a presentation on the clinical trial results for the drug Avastin for patients recently diagnosed with an aggressive form of brain cancer, glioblastoma multiforme (GBM), according to an article by Clinton Leaf appearing in the New York Times, which is summarized below, with our comments added. The presentation by Dr. Mark R. Gilbert, professor of neuro-oncology at the University of Texas [...]

Contact Info

110 Riverbend Avenue, Suite 100, Powell, OH 43065

Phone: 614.389.4004

Fax: 866.259.4324

Recent News